Lucentis Intravitreal Injection
Ranibizumab
0.5 mg/0.05 ml
Novartis (Bangladesh) Ltd.
| Pack size | 0.23 ml vial |
|---|---|
| Unite Price | 37978.00 BDT |
Indications
Lucentis Intravitreal Injection is used for:
Wet ARMD, Central retinal vein occlusion, Diabetic macular edema
Adult Dose
Intravitreal
Neovascular (wet) age-related macular degeneration
Adult: 0.5 mg (0.05 mL of 10 mg/mL) mthly into the affected eye as a single dose. Continue treatment until visual acuity is stable for 3 consecutive mth. Doses are given at intervals of at least 1 mth.
Macular oedema secondary to retinal vein occlusion
Adult: 0.5 mg mthly into the affected eye as a single dose for 6 months. Doses are given at intervals of at least 1 mth.
Diabetic Macular Edema, Diabetic Retinopathy with DME
0.3 mg (0.05 mL of 6 mg/mL) administer by intravitreal injection once a month (approximately every 28 days).
Child Dose
Renal Dose
Administration
Contra Indications
Active or suspected ocular or periocular infection, active severe intraocular inflammation, signs of irreversible ischaemic visual function loss in patients w/ retinal vein occlusion.
Precautions
Patient w/ risk factors for retinal pigment epithelial tears, history of stroke or transient ischaemic attack, uncontrolled HTN, previous intravitreal inj, active systemic infections, proliferative diabetic retinopathy, diabetic macular oedema due to type 1 DM. Discontinue treatment if rhegmatogenous retinal detachment or stage 3 or 4 macular hole develops. Diabetic patients w/ glycosylated Hb over 12%.
Lactation: Unknown if distributed in milk; use caution
Pregnancy-Lactation
Pregnancy
There are no adequate and well-controlled studies in pregnant women
Administration of ranibizumab to pregnant monkeys throughout the period of organogenesis resulted in a low incidence of skeletal abnormalities at intravitreal doses 13-times the predicted human exposure (based on maximal serum trough levels [Cmax]) after a single eye treatment at the recommended clinical dose
Ranibizumab should be given to a pregnant woman only if clearly needed
Lactation
There are no data available on presence of ranibizumab in human milk; effects of ranibizumab on breastfed infant or effects of ranibizumab on milk production/excretion; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from ranibizumab
Interactions
May enhance the adverse/toxic effect of belimumab. Serious intraocular inflammation may occur when used adjunctively w/ verteporfin photodynamic therapy (PDT).
Side Effects
Side effects of Ranibizumab :
>10%
Conjunctival hemorrhage (43-77%), Eye pain (17-37%), Vitreous floaters (3-32%), Incr IOP (8-24%), Vitreous detachment (7-22%), Eye irritation (4-19%), Intraocular inflammation (5-18%), Headache (2-15%), Upper resp tract infection (2-15%), Retinal disorder (13%), Blepharitis (3-13%), Retinal degeneration (1-11%)
1-10%
Conjunctival hyperemia (9%), Posterior capsule opacification (8%), Injection site hemorrhage (5%), Vitreous hemorrhage (4%)
Mode of Action
Humanized monoclonal antibody to VEGF-A, inhibits VEGF-A-induced ocular neovascularization.
Note
Lucentis 0.5 mg/0.05 ml Intravitreal Injection generic name is Ranibizumab. Lucentis 0.5 mg/0.05 ml Intravitreal Injection is manufactured by Novartis (Bangladesh) Ltd.Lucentis is availble in all over Bangladesh.
Mes BD drug index information on Lucentis Intravitreal Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.